What is Elasmogen?
Founded in 2016, Elasmogen is a specialized biopharmaceutical firm headquartered in Aberdeen, Scotland. The company is dedicated to the discovery and development of next-generation soloMER products, which are engineered to provide highly specific and potent therapeutic interventions. Its core focus areas include the treatment of solid-tumor cancers, systemic inflammatory diseases, and complex inflammatory conditions of the gut. By utilizing its unique soloMER platform, Elasmogen aims to overcome the limitations of traditional biologics, offering superior tissue penetration and stability. As a key entity within the United Kingdom's thriving biologics cluster, the company maintains a strategic focus on high-value therapeutic segments, positioning itself as a critical innovator in the pursuit of precision medicine and targeted patient care.
How much funding has Elasmogen raised?
Elasmogen has raised a total of $13.9M across 3 funding rounds:
Unspecified
$1.5M
Private Equity
$2.6M
Other Financing Round
$9.9M
Unspecified (2017): $1.5M with participation from Deepbridge Capital and Scottish Investment Bank
Private Equity (2020): $2.6M led by Deepbridge Capital
Other Financing Round (2022): $9.9M supported by BFG International
Key Investors in Elasmogen
Deepbridge Capital
Deepbridge Syndicate is a private investor network that caters to experienced investors and family offices, allowing them to create personalized portfolios of innovative Life Sciences and Technology companies.
Scottish Investment Bank
Founded in 1991, Scottish Enterprise is a national economic development agency and a non-departmental public body of the Scottish Government.
BFG International
Established in 1975, BFG International manufactures composites and provides advanced solutions for various industrial sectors including renewable energy and automotive.
What's next for Elasmogen?
Looking ahead, Elasmogen is poised to leverage its recent capital injection to scale its operational infrastructure and expedite its clinical trial milestones. The strategic roadmap involves deepening the validation of its soloMER pipeline, with a particular emphasis on solid-tumor oncology applications where the need for highly specific, localized treatment remains acute. Furthermore, the company is expected to pursue collaborative partnerships that could enhance its market reach and accelerate the commercialization of its therapeutic assets. As the firm matures, the focus will likely shift toward establishing a more robust regulatory and manufacturing framework, ensuring that its innovative biologics can meet the rigorous demands of international healthcare markets. This trajectory suggests a sustained commitment to long-term value creation for stakeholders and patients alike.
See full Elasmogen company page
